APO RESEARCH · REPORT
Cefotaxime Sodium API
Cefotaxime sodium is the sodium salt form of cefotaxime, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Cefotaxime sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, cefotaxime sodium is more active against gram-negative bacteria and less active against gram-positive bacteria.
Product & engineering
Understand the product.
Cefotaxime sodium is the sodium salt form of cefotaxime, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Cefotaxime sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, cefotaxime sodium is more active against gram-negative bacteria and less active against gram-positive bacteria.
Selected research
Industry Research
Cefotaxime Sodium API Industry Research Report 2026
Market perspective
Cefotaxime sodium is the sodium salt form of cefotaxime, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Cefotaxime sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, cefotaxime sodium is more active against gram-negative bacteria and less active against gram-positive bacteria.
Market competition is intense. REYOUNG, Nectar Lifesciences, Medya Pharma, Sandoz, Kelun, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 5 manufacturers accountted for 57.98% market share in 2019.
Report Scope
Read the full market overview
This report quantifies the global Cefotaxime Sodium API market in terms of revenue (US$ million) and, where applicable, sales volume (MT), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/MT) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cefotaxime Sodium API Market by Company
REYOUNG
Nectar Lifesciences
Medya Pharma
Sandoz
Kelun
NCPC
Aurobindo Pharma
United Laboratories
Orchid Pharma
CSPC
Kopran
Covalent
ACS Dobfar
Dawnrays
Sterile India
Cefotaxime Sodium API Segment by Type
ChP
USP
EP
Cefotaxime Sodium API Segment by Application
Single Injection
Compound Injection
Cefotaxime Sodium API Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cefotaxime Sodium API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cefotaxime Sodium API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cefotaxime Sodium API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cefotaxime Sodium API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cefotaxime Sodium API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cefotaxime Sodium API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- ChP
- USP
- EP
Applications
- Single Injection
- Compound Injection
Companies covered
- REYOUNG
- Nectar Lifesciences
- Medya Pharma
- Sandoz
- Kelun
- NCPC
- Aurobindo Pharma
- United Laboratories
- Orchid Pharma
- CSPC
- Kopran
- Covalent
- ACS Dobfar
- Dawnrays
- Sterile India
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Cefotaxime Sodium API Market Size (2021-2032)
- 2.2.2 Global Cefotaxime Sodium API Sales (2021-2032)
- 2.2.3 Global Cefotaxime Sodium API Market Average Price (2021-2032)
- 2.3 Cefotaxime Sodium API by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 ChP
- 2.3.3 USP
- 2.3.4 EP
- 2.4 Cefotaxime Sodium API by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Single Injection
- 2.4.3 Compound Injection
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Cefotaxime Sodium API Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Cefotaxime Sodium API Sales (MT) of Manufacturers (2021-2026)
- 3.3 Global Cefotaxime Sodium API Revenue of Manufacturers (2021-2026)
- 3.4 Global Cefotaxime Sodium API Average Price by Manufacturers (2021-2026)
- 3.5 Global Cefotaxime Sodium API Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Cefotaxime Sodium API, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Cefotaxime Sodium API, Product Type & Application
- 3.8 Global Manufacturers of Cefotaxime Sodium API, Established Date
- 3.9 Global Cefotaxime Sodium API Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 REYOUNG
- 4.1.1 REYOUNG Company Information
- 4.1.2 REYOUNG Business Overview
- 4.1.3 REYOUNG Cefotaxime Sodium API Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 REYOUNG Cefotaxime Sodium API Product Portfolio
- 4.1.5 REYOUNG Recent Developments
- 4.2 Nectar Lifesciences
- 4.2.1 Nectar Lifesciences Company Information
- 4.2.2 Nectar Lifesciences Business Overview
- 4.2.3 Nectar Lifesciences Cefotaxime Sodium API Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Nectar Lifesciences Cefotaxime Sodium API Product Portfolio
- 4.2.5 Nectar Lifesciences Recent Developments
- 4.3 Medya Pharma
- 4.3.1 Medya Pharma Company Information
- 4.3.2 Medya Pharma Business Overview
- 4.3.3 Medya Pharma Cefotaxime Sodium API Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Medya Pharma Cefotaxime Sodium API Product Portfolio
- 4.3.5 Medya Pharma Recent Developments
- 4.4 Sandoz
- 4.4.1 Sandoz Company Information
- 4.4.2 Sandoz Business Overview
- 4.4.3 Sandoz Cefotaxime Sodium API Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sandoz Cefotaxime Sodium API Product Portfolio
- 4.4.5 Sandoz Recent Developments
- 4.5 Kelun
- 4.5.1 Kelun Company Information
- 4.5.2 Kelun Business Overview
- 4.5.3 Kelun Cefotaxime Sodium API Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Kelun Cefotaxime Sodium API Product Portfolio
- 4.5.5 Kelun Recent Developments
- 4.6 NCPC
- 4.6.1 NCPC Company Information
- 4.6.2 NCPC Business Overview
- 4.6.3 NCPC Cefotaxime Sodium API Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 NCPC Cefotaxime Sodium API Product Portfolio
- 4.6.5 NCPC Recent Developments
- 4.7 Aurobindo Pharma
- 4.7.1 Aurobindo Pharma Company Information
- 4.7.2 Aurobindo Pharma Business Overview
- 4.7.3 Aurobindo Pharma Cefotaxime Sodium API Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Aurobindo Pharma Cefotaxime Sodium API Product Portfolio
- 4.7.5 Aurobindo Pharma Recent Developments
- 4.8 United Laboratories
- 4.8.1 United Laboratories Company Information
- 4.8.2 United Laboratories Business Overview
- 4.8.3 United Laboratories Cefotaxime Sodium API Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 United Laboratories Cefotaxime Sodium API Product Portfolio
- 4.8.5 United Laboratories Recent Developments
- 4.9 Orchid Pharma
- 4.9.1 Orchid Pharma Company Information
- 4.9.2 Orchid Pharma Business Overview
- 4.9.3 Orchid Pharma Cefotaxime Sodium API Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Orchid Pharma Cefotaxime Sodium API Product Portfolio
- 4.9.5 Orchid Pharma Recent Developments
- 4.10 CSPC
- 4.10.1 CSPC Company Information
- 4.10.2 CSPC Business Overview
- 4.10.3 CSPC Cefotaxime Sodium API Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 CSPC Cefotaxime Sodium API Product Portfolio
- 4.10.5 CSPC Recent Developments
- 4.11 Kopran
- 4.11.1 Kopran Company Information
- 4.11.2 Kopran Business Overview
- 4.11.3 Kopran Cefotaxime Sodium API Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Kopran Cefotaxime Sodium API Product Portfolio
- 4.11.5 Kopran Recent Developments
- 4.12 Covalent
- 4.12.1 Covalent Company Information
- 4.12.2 Covalent Business Overview
- 4.12.3 Covalent Cefotaxime Sodium API Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Covalent Cefotaxime Sodium API Product Portfolio
- 4.12.5 Covalent Recent Developments
- 4.13 ACS Dobfar
- 4.13.1 ACS Dobfar Company Information
- 4.13.2 ACS Dobfar Business Overview
- 4.13.3 ACS Dobfar Cefotaxime Sodium API Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 ACS Dobfar Cefotaxime Sodium API Product Portfolio
- 4.13.5 ACS Dobfar Recent Developments
- 4.14 Dawnrays
- 4.14.1 Dawnrays Company Information
- 4.14.2 Dawnrays Business Overview
- 4.14.3 Dawnrays Cefotaxime Sodium API Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Dawnrays Cefotaxime Sodium API Product Portfolio
- 4.14.5 Dawnrays Recent Developments
- 4.15 Sterile India
- 4.15.1 Sterile India Company Information
- 4.15.2 Sterile India Business Overview
- 4.15.3 Sterile India Cefotaxime Sodium API Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Sterile India Cefotaxime Sodium API Product Portfolio
- 4.15.5 Sterile India Recent Developments
5 Global Cefotaxime Sodium API Market Scenario by Region
- 5.1 Global Cefotaxime Sodium API Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Cefotaxime Sodium API Sales by Region: 2021-2032
- 5.2.1 Global Cefotaxime Sodium API Sales by Region: 2021-2026
- 5.2.2 Global Cefotaxime Sodium API Sales by Region: 2027-2032
- 5.3 Global Cefotaxime Sodium API Revenue by Region: 2021-2032
- 5.3.1 Global Cefotaxime Sodium API Revenue by Region: 2021-2026
- 5.3.2 Global Cefotaxime Sodium API Revenue by Region: 2027-2032
- 5.4 North America Cefotaxime Sodium API Market Facts & Figures by Country
- 5.4.1 North America Cefotaxime Sodium API Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Cefotaxime Sodium API Sales by Country (2021-2032)
- 5.4.3 North America Cefotaxime Sodium API Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Cefotaxime Sodium API Market Facts & Figures by Country
- 5.5.1 Europe Cefotaxime Sodium API Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Cefotaxime Sodium API Sales by Country (2021-2032)
- 5.5.3 Europe Cefotaxime Sodium API Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Cefotaxime Sodium API Market Facts & Figures by Country
- 5.6.1 Asia Pacific Cefotaxime Sodium API Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Cefotaxime Sodium API Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Cefotaxime Sodium API Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Cefotaxime Sodium API Market Facts & Figures by Country
- 5.7.1 South America Cefotaxime Sodium API Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Cefotaxime Sodium API Sales by Country (2021-2032)
- 5.7.3 South America Cefotaxime Sodium API Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Cefotaxime Sodium API Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Cefotaxime Sodium API Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Cefotaxime Sodium API Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Cefotaxime Sodium API Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Cefotaxime Sodium API Sales by Type (2021-2032)
- 6.1.1 Global Cefotaxime Sodium API Sales by Type (2021-2032) & (MT)
- 6.1.2 Global Cefotaxime Sodium API Sales Market Share by Type (2021-2032)
- 6.2 Global Cefotaxime Sodium API Revenue by Type (2021-2032)
- 6.2.1 Global Cefotaxime Sodium API Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Cefotaxime Sodium API Revenue Market Share by Type (2021-2032)
- 6.3 Global Cefotaxime Sodium API Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Cefotaxime Sodium API Sales by Application (2021-2032)
- 7.1.1 Global Cefotaxime Sodium API Sales by Application (2021-2032) & (MT)
- 7.1.2 Global Cefotaxime Sodium API Sales Market Share by Application (2021-2032)
- 7.2 Global Cefotaxime Sodium API Revenue by Application (2021-2032)
- 7.2.1 Global Cefotaxime Sodium API Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Cefotaxime Sodium API Revenue Market Share by Application (2021-2032)
- 7.3 Global Cefotaxime Sodium API Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Cefotaxime Sodium API Value Chain Analysis
- 8.1.1 Cefotaxime Sodium API Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Cefotaxime Sodium API Production Mode & Process
- 8.2 Cefotaxime Sodium API Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Cefotaxime Sodium API Distributors
- 8.2.3 Cefotaxime Sodium API Customers
9 Global Cefotaxime Sodium API Analyzing Market Dynamics
- 9.1 Cefotaxime Sodium API Industry Trends
- 9.2 Cefotaxime Sodium API Industry Drivers
- 9.3 Cefotaxime Sodium API Industry Opportunities and Challenges
- 9.4 Cefotaxime Sodium API Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst